Neurology

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded by questions.

Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

Approved agents target calcitonin gene-related peptides to bring pain relief to affected patients.

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.

Factors that need to be considered when determining patient candidacy for over-the-counter herbal products and nutritional supplements available as preventive therapy for migraine and recommendations for educating patients about their use.

Survival for patients with glioblastoma tumors is poor, with close to 75% of patients dying within 2 years of diagnosis and 95% dying within 5 years.

The updated label follows controversy surrounding aducanumab’s approval in June 2021, despite hesitation from experts on the drug’s efficacy.

Preventive therapies available for patients who require migraine prophylaxis and factors that impact treatment selection.

Jennifer L. Mazan, PharmD, describes the role of CGRP antagonists as acute migraine treatment and shares considerations for selecting and using these therapies.

The study authors said that these findings could be used to help identify healthy people who are at risk for the condition before they have symptoms.

Special considerations for counseling patients and prescribing lasmiditan, a targeted 5-HT1F therapy approved as acute migraine treatment.

Timothy Smith, MD, RPh, FACP, AQH, describes goals of therapy for the acute treatment of migraine and reacts to current treatment limitations associated with available drug therapies.

Pharmacists should assess patient comorbidities, symptoms, and history to ensure the selection of the most appropriate migraine medication.

The researchers noted that during high-risk pregnancies, special monitoring and care throughout the pregnancy is mandatory.

Amy R. Dunleavy, PharmD, highlights various drug therapies used for the acute treatment of migraine and provides recommendations for appropriate use.

A panel discussion regarding the underdiagnosis and burden of migraine attacks on patients and the rationale for educating the community about signs and symptoms.

A study comparing once-monthly injectable galcanezumab-gnlm with rimegepant has been planned to support the assessment of potential treatments to prevent migraines.

Popular among European royalty, the consumption of human brain emerged in the 17th century as a cure to ailments of the mind.

The FDA recently approved the amyloid beta-directed antibody indicated for the treatment of the progressive disease.

The results of the study are consistent with several large-scale epidemiological studies that show an association between Parkinson and inflammatory bowel diseases, such as ulcerative colitis and Crohn disease.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.

Rimegepant is indicated for adult patients with episodic migraines.

Matthew Harms, a medical consultant and care center director at the MDA and associate professor of neurology at Columbia University Medical Center, to discuss new treatments and anticipated developments for ALS over the next year.

Erenumab-aooe (Aimovig, Amgen) is indicated for the preventive treatment of migraine in adults, making it the first approved preventive migraine treatment of its kind.

The historical and cultural foundations of the use of psychedelic drugs, the failure of the war on drugs in the United States, and multiple examples of other countries successfully legalizing psychedelics without societal problems developing as a result make a clear argument for the legalization of psychedelic medicine.